Alerts will be sent to your verified email
Verify Email
BALAXI
|
Balaxi Pharma.
|
Trident Lifeline
|
Fredun Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
29.33 % | 35.94 % | 8.53 % |
|
5yr average Equity Multiplier
|
1.4 | 1.91 | 3.02 |
|
5yr Average Asset Turnover Ratio
|
1.5 | 0.9 | 1.01 |
|
5yr Avg Net Profit Margin
|
11.83 % | 17.11 % | 2.89 % |
|
Price to Book
|
1.49 | 5.68 | 2.41 |
|
P/E
|
11.78 | 51.48 | 16.76 |
|
5yr Avg Cash Conversion Cycle
|
133.11 Days | 94.4 Days | 137.13 Days |
|
Inventory Days
|
68.7 Days | 68.55 Days | 140.46 Days |
|
Days Receivable
|
81.67 Days | 104.41 Days | 52.11 Days |
|
Days Payable
|
60.92 Days | 126.58 Days | 131.93 Days |
|
5yr Average Interest Coverage Ratio
|
92.41 | 17.94 | 2.31 |
|
5yr Avg ROCE
|
40.34 % | 29.15 % | 16.75 % |
|
5yr Avg Operating Profit Margin
|
18.05 % | 16.89 % | 8.32 % |
|
5 yr average Debt to Equity
|
0.05 | 0.34 | 0.86 |
|
5yr CAGR Net Profit
|
n/a | 9.93 % | 52.4 % |
|
5yr Average Return on Assets
|
20.09 % | 15.87 % | 3.05 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
65.99 % | 63.04 % | 48.93 % |
|
Share Pledged by Promoters
|
0.0 | 3.46 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.87 % | -6.53 % | -2.34 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Balaxi Pharma.
|
Trident Lifeline
|
Fredun Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Drug Delivery Break-Up
|
Drug Delivery Break-Up
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|